mirtazapine + gemcitabine

Mirtazapine + gemcitabine is an investigational combination therapy consisting of mirtazapine, a tetracyclic antidepressant, and gemcitabine, a nucleoside analog chemotherapeutic agent. This combination has been studied primarily in the context of metastatic pancreatic cancer to address both the psychological (depression and anxiety) and physical (cachexia) complications associated with advanced malignancy. Mirtazapine acts as an antagonist at central presynaptic alpha-2 adrenergic inhibitory autoreceptors and heteroreceptors, increasing noradrenergic and serotonergic activity; it also antagonizes specific serotonin receptors (5-HT2 and 5-HT3), contributing to its antidepressant effects. Gemcitabine is phosphorylated intracellularly to active metabolites that inhibit DNA synthesis by competing with deoxycytidine triphosphate for incorporation into DNA, leading to masked chain termination and apoptosis in malignant cells. Preclinical studies suggest that mirtazapine may improve food intake and body weight in cachectic mice treated with gemcitabine without affecting tumor growth[1][2]. Clinical trials have explored this combination for improving quality of life, appetite, mood symptoms, chemotherapy-induced nausea/vomiting, response rate, progression-free survival, and overall survival in patients with metastatic pancreatic cancer[3][8].